ClinicalTrials.gg
CompletedNCT01664923STRIVEUpdated Jan 30, 2019Results posted

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

A Phase 2 interventional study of Enzalutamide and Bicalutamide in Prostate Cancer, sponsored by Pfizer. Completed at 109 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
18th of 125
396 · median 52
Started
2012
with 4 others
Phase 2
65 of 125
8 open now
Registered
12th of 125
by date
Lead sponsor
12 of 125
Pfizer

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 18th largest by enrollment, is one of 5 that started in 2012, is one of 65 in phase 2, and was the 12th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen deprivation therapy.

Read the detailed description

This study is a multicenter phase 2, randomized, double-blind, efficacy and safety study of enzalutamide (160 mg/day) vs. bicalutamide (50 mg/day) in patients with recurrent prostate cancer who have serologic and/or radiographic disease progression despite primary androgen deprivation therapy.

Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs, physical examinations, and safety laboratory evaluations.

Following study unblinding, study patients receiving enzalutamide or bicalutamide at the time of unblinding and qualifying patients randomized to bicalutamide who discontinued prior to unblinding will be offered the opportunity to receive open label enzalutamide treatment.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • enzalutamide
  • MDV3100
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Males age 18 or older;
  • or cytologically confirmed adenocarcinoma of the prostate;
  • Ongoing androgen deprivation therapy;
  • Serum testosterone level ≤ 50 ng/dL (1.73 nmol/L) at the Screening visit;
  • Progressive disease at study entry defined by prostate-specific antigen (PSA) progression and/or radiographic progression that occurred while the patient was on primary androgen deprivation therapy;
  • Asymptomatic or mildly symptomatic from prostate cancer;
  • (ECOG) performance status of 0-1;
  • Estimated of ≥ 12 months;
  • Able to swallow the study drug and comply with study requirements.

Exclusion Criteria:

  • Severe concurrent disease, infection, or co-morbidity;
  • Known or suspected or active ;
  • History of another invasive within the previous 5 years other than treated non-melanomatous skin cancer and American Joint Committee on Cancer (AJCC) Stage 0 or Stage 1 cancers that have a remote probability of recurrence;
  • \< 1,500/µL, or count \< 100,000/µL, or \< 9 g/dL at the Screening visit;
  • Total , (ALT) or aspartate aminotransferase (AST) > 2.5 times the (ULN) at the Screening visit;
  • Creatinine > 2 mg/dL at the Screening visit;
  • Albumin \< 3.0 g/dL at the Screening visit;
  • History of seizure or any condition that may predispose to seizure;
  • cardiovascular disease;
  • Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months);
  • Major surgery within 4 weeks of enrollment;
  • Use of opiate analgesics for pain from prostate cancer within 4 weeks of enrollment;
  • Radiation therapy for treatment of the primary tumor within 3 weeks of enrollment;
  • Prior radiation or radionuclide therapy for treatment of distant ;
  • Prior ketoconazole, abiraterone, or cytotoxic chemotherapy for prostate cancer;
  • Treatment with hormonal therapy or biologic therapy for prostate cancer within 4 weeks of enrollment;
  • Use of antiandrogens within 4 weeks prior to enrollment;
  • Prior disease progression, as assessed by the Investigator, while receiving bicalutamide;
  • Participation in a previous clinical trial of enzalutamide or an agent that inhibits the androgen receptor or androgen synthesis (patients who received placebo are acceptable);
  • Use of an investigational agent within 4 weeks of enrollment;
  • Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic for prostate cancer within 4 weeks of enrollment;
  • Any condition or reason that, in the opinion of the Investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data.

Open-Label Treatment Period:

Inclusion Criteria:

  • Received randomized double blind treatment in MDV3100-09 as follows:

    • Randomized to enzalutamide and receiving enzalutamide at the time of study unblinding;
    • Randomized to bicalutamide and receiving bicalutamide at the time of study unblinding;
    • Randomized to bicalutamide and discontinued bicalutamide before study unblinding;
  • Willing to maintain androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) agonist/antagonist or has had a bilateral orchiectomy.

Exclusion Criteria:

  • Is currently or has taken commercially available enzalutamide (Xtandi) prior to participation in this open-label extension;
  • Discontinued enzalutamide during the double-blind portion of the study prior to unblinding;
  • Has any clinically significant cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, infectious, metabolic, neurologic, psychiatric, psychologic, pulmonary, or renal disorder or any other condition, including excessive alcohol or drug abuse, or secondary malignancy, that may interfere with study participation in the opinion of the investigator or medical monitor;
  • Has a current or previously treated brain metastasis or leptomeningeal disease;
  • Has a history of seizure or any condition that may predispose to seizure (eg, prior cortical stroke or significant brain trauma);
  • Has a history of loss of consciousness or within 12 months of open label day 1;
  • Has taken cytotoxic chemotherapy or investigational therapy within 4 weeks before enrollment (open label day 1).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Enzalutamide 160 mg/day orally

    Drug: Enzalutamide

  • Active comparator
    Bicalutamide

    50 mg/day orally

    Drug: Bicalutamide

Interventions

  • 160 mg, daily, by mouth.

    Also known as: MDV3100, Xtandi

  • 50 mg, daily, by mouth

    Also known as: Casodex

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as time from randomization to earliest objective evidence of prostate specific-antigen (PSA) progression, radiographic progression, or death on study. PSA progression was defined as ≥ 25% increase in PSA with an absolute increase ≥ 2 ng/mL above the nadir and was to be confirmed by a second consecutive assessment. Radiographic progression in bone was based on The Prostate Cancer Clinical Trials Working Group (PCWG2) guidelines defined as at least 2 new lesions on bone scan. Radiographic progression in soft tissue on Computerized Tomography/Magnetic Resonance Imaging (CT/MRI) was based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CT/MRI and bone scans were read locally by the same radiologist (or nuclear medicine physician for interpretation of bone scans) whenever possible. Participants not known to have had a PFS event at the time of the analysis data cutoff were censored at the date of last assessment.

    Time frame: From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.

Secondary outcomes

  1. Time to PSA Progression

    PSA progression was defined as ≥ 25% increase in PSA with an absolute increase ≥ 2 ng/mL above the nadir and was to be confirmed by a second consecutive assessment at least 3 weeks later. Participants not known to have had PSA progression were censored at the date of last PSA assessment.

    Time frame: From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.

  2. Percentage of Participants With a PSA Response ≥ 50%

    PSA response was defined as a reduction in PSA of at least 50% from baseline at any post baseline assessment confirmed by a second PSA assessment at least 3 weeks later.

    Time frame: From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.

  3. Duration of Radiographic PFS

    Duration of radiographic PFS was defined as the time from randomization to the earliest objective evidence of radiographic disease progression or death on study and was to be evaluated for participants with metastatic disease at study entry. Radiographic disease progression in bone was based on PCWG2 guidelines defined as at least 2 new lesions on bone scan. Radiographic disease progression in soft tissue on CT/MRI was based on RECIST 1.1. CT/MRI and bone scans were read locally by the same radiologist (or nuclear medicine physician for interpretation of bone scans) whenever possible. Participants not known to have had radiographic progression at the time of analysis data cutoff were censored at the date of last radiographic assessment.

    Time frame: From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.

  4. Quality of Life: Time to Degradation of Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess patient function in 4 domains: physical, social/family, emotional, and functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score (0 to 156) with higher scores representing better quality of life. Time to degradation of FACT-P was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the global FACT-P score for each participant. Participants with no score degradation at the time of analysis data cutoff were censored at the date of last assessment showing no degradation.

    Time frame: From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.

  5. Best Overall Soft Tissue Response

    Best overall soft tissue response is defined as partial response (PR) or complete response (CR) while on study treatment based on investigator assessment of target, nontarget, and new lesions using RECIST 1.1. Only participants in the metastatic population with measurable soft tissue disease (at least 1 target lesion identified per RECIST 1.1) at screening were included in the analysis. All percentages are based on number of participants with metastatic and measurable soft tissue disease at screening in each treatment group.

    Time frame: From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.

  6. Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. A treatment emergent AE defined as an event that emerged during treatment period (From first dose of study drug until end of open label phase \[up to maximum duration of 65 months\]) that was absent before treatment, or worsened during treatment period relative to pre-treatment state. AE included both serious and non- SAE. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An AE was considered related to study drug if event was assessed by investigator as probably or possibly related.

    Time frame: From first dose of study drug until the end of open label phase (up to maximum duration of 65 months)

07

Results

Posted May 23, 2016

Participant flow

Period1:Double Blind Phase-29 Months
Participant flow — Period1:Double Blind Phase-29 Months
MilestoneEnzalutamideBicalutamide Then Enzalutamide
Started198198
Received study treatment197198
Completed9338
Not completed105160
Withdrew: Death86
Withdrew: Lost to follow-up01
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject128
Withdrew: Disease progression65132
Withdrew: Adverse event149
Withdrew: Other34
Withdrew: Randomized, but not treated10
Period 2: Open-label Phase-36 Months
Participant flow — Period 2: Open-label Phase-36 Months
MilestoneEnzalutamideBicalutamide Then Enzalutamide
Started9338
Treated9337
Completed5215
Not completed4123
Withdrew: Death31
Withdrew: On treatment11
Withdrew: Disease progression289
Withdrew: Other31
Withdrew: Adverse event47
Withdrew: Withdrawal by subject24

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as time from randomization to earliest objective evidence of prostate specific-antigen (PSA) progression, radiographic progression, or death on study. PSA progression was defined as ≥ 25% increase in PSA with an absolute increase ≥ 2 ng/mL above the nadir and was to be confirmed by a second consecutive assessment. Radiographic progression in bone was based on The Prostate Cancer Clinical Trials Working Group (PCWG2) guidelines defined as at least 2 new lesions on bone scan. Radiographic progression in soft tissue on Computerized Tomography/Magnetic Resonance Imaging (CT/MRI) was based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CT/MRI and bone scans were read locally by the same radiologist (or nuclear medicine physician for interpretation of bone scans) whenever possible. Participants not known to have had a PFS event at the time of the analysis data cutoff were censored at the date of last assessment.

Time frame:
From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsEnzalutamideBicalutamide
Progression Free Survival (PFS)19.4 (16.5 to NA)5.7 (5.6 to 8.1)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 (P-value based on log-rank test stratified by disease stage at study entry as reported on the case report form (CRF).) · Hazard ratio (hr): 0.240 · 95% CI 0.181 to 0.320Hazard ratio is based on a Cox regression model (with treatment as the only covariate) stratified by disease stage at study entry and is relative to bicalutamide with \< 1 favoring enzalutamide.
SecondaryTime to PSA Progression

PSA progression was defined as ≥ 25% increase in PSA with an absolute increase ≥ 2 ng/mL above the nadir and was to be confirmed by a second consecutive assessment at least 3 weeks later. Participants not known to have had PSA progression were censored at the date of last PSA assessment.

Time frame:
From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.
Reported as:
Median · months
Time to PSA Progression
monthsEnzalutamideBicalutamide
Time to PSA ProgressionNA (19.4 to NA)8.3 (5.7 to 8.5)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 (P-value based on log-rank test stratified by disease stage at study entry as reported on the CRF.) · Hazard ratio (hr): 0.190 · 95% CI 0.137 to 0.264Hazard ratio is based on a Cox regression model (with treatment as the only covariate) stratified by disease stage at study entry and is relative to bicalutamide with \< 1 favoring enzalutamide.
SecondaryPercentage of Participants With a PSA Response ≥ 50%

PSA response was defined as a reduction in PSA of at least 50% from baseline at any post baseline assessment confirmed by a second PSA assessment at least 3 weeks later.

Time frame:
From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.
Reported as:
Number · percentage of participants
Percentage of Participants With a PSA Response ≥ 50%
percentage of participantsEnzalutamideBicalutamide
Percentage of Participants With a PSA Response ≥ 50%81.3 (75.0 to 86.5)31.3 (24.8 to 38.3)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in rates: 50.0 · 95% CI 41.4 to 58.5Enzalutamide response rate minus bicalutamide response rate.
SecondaryDuration of Radiographic PFS

Duration of radiographic PFS was defined as the time from randomization to the earliest objective evidence of radiographic disease progression or death on study and was to be evaluated for participants with metastatic disease at study entry. Radiographic disease progression in bone was based on PCWG2 guidelines defined as at least 2 new lesions on bone scan. Radiographic disease progression in soft tissue on CT/MRI was based on RECIST 1.1. CT/MRI and bone scans were read locally by the same radiologist (or nuclear medicine physician for interpretation of bone scans) whenever possible. Participants not known to have had radiographic progression at the time of analysis data cutoff were censored at the date of last radiographic assessment.

Time frame:
From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.
Reported as:
Median · months
Duration of Radiographic PFS
monthsEnzalutamideBicalutamide
Duration of Radiographic PFSNA (16.7 to NA)8.3 (8.1 to 11.1)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.324 · 95% CI 0.211 to 0.497Hazard ratio is based on an unstratified Cox-regression model (with treatment as the only covariate) and is relative to bicalutamide with \< 1 favoring enzalutamide.
SecondaryQuality of Life: Time to Degradation of Functional Assessment of Cancer Therapy - Prostate (FACT-P)

The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess patient function in 4 domains: physical, social/family, emotional, and functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain, as well as a global quality of life score (0 to 156) with higher scores representing better quality of life. Time to degradation of FACT-P was defined as the time from randomization to first assessment with at least a 10-point decrease from baseline in the global FACT-P score for each participant. Participants with no score degradation at the time of analysis data cutoff were censored at the date of last assessment showing no degradation.

Time frame:
From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.
Reported as:
Median · months
Quality of Life: Time to Degradation of Functional Assessment of Cancer Therapy - Prostate (FACT-P)
monthsEnzalutamideBicalutamide
Quality of Life: Time to Degradation of Functional Assessment of Cancer Therapy - Prostate (FACT-P)8.4 (6.3 to 11.4)8.3 (6.1 to 11.1)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = 0.4945 (This secondary endpoint was not adjusted for multiple comparisons.) · Hazard ratio (hr): 0.910 · 95% CI 0.695 to 1.192Hazard ratio is based on a Cox regression model (with treatment as the only covariate) stratified by disease stage at study entry and is relative to bicalutamide with \< 1 favoring enzalutamide.
SecondaryBest Overall Soft Tissue Response

Best overall soft tissue response is defined as partial response (PR) or complete response (CR) while on study treatment based on investigator assessment of target, nontarget, and new lesions using RECIST 1.1. Only participants in the metastatic population with measurable soft tissue disease (at least 1 target lesion identified per RECIST 1.1) at screening were included in the analysis. All percentages are based on number of participants with metastatic and measurable soft tissue disease at screening in each treatment group.

Time frame:
From randomization until the data cut-off date of 09 February 2015, median duration of treatment was 14.7 months in the enzalutamide arm and 8.4 months in the bicalutamide arm.
Reported as:
Number · percentage of participants
Best Overall Soft Tissue Response
percentage of participantsEnzalutamideBicalutamide
Best Overall Soft Tissue Response60.0 (42.11 to 76.13)14.0 (5.30 to 27.93)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Cochran-Mantel-Haenszel · p = <0.0001 (This secondary endpoint was not adjusted for multiple comparisons.) · Difference in objective response rate: 46.05 · 95% CI 26.79 to 65.30Based on unstratified Cochran-Mantel-Haenszel mean score test.
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. A treatment emergent AE defined as an event that emerged during treatment period (From first dose of study drug until end of open label phase \[up to maximum duration of 65 months\]) that was absent before treatment, or worsened during treatment period relative to pre-treatment state. AE included both serious and non- SAE. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An AE was considered related to study drug if event was assessed by investigator as probably or possibly related.

Time frame:
From first dose of study drug until the end of open label phase (up to maximum duration of 65 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsEnzalutamideDB Phase: BicalutamideOpen Label Phase: Bicalutamide Crossover to Enzalutamide
Any AE96.490.497.3
AE Leading to Study Drug Discontinuation16.213.124.3
AE Leading to Death4.63.08.1
Serious AE38.630.343.2
AE Related to Study Drug66.553.570.3
Serious AE Related to Study Drug7.63.52.7

Adverse events

Collected over From first dose of study drug until the end of open label phase (up to maximum duration of 65 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide—76/197 (38.6%)187/197 (94.9%)
DB Phase: Bicalutamide—60/198 (30.3%)179/198 (90.4%)
Open Label Phase: Bicalutamide Crossover to Enzalutamide—16/37 (43.2%)36/37 (97.3%)
Most frequent serious events
Showing 10 of 203
Most frequent serious events
EventEnzalutamideDB Phase: BicalutamideOpen Label Phase: Bicalutamide Crossover to Enzalutamide
AnaemiaBlood and lymphatic system disorders4/1974/1982/37
Cardiac failure congestiveCardiac disorders5/1972/1982/37
Cystitis radiationInjury, poisoning and procedural complications0/1970/1982/37
Haemorrhagic strokeNervous system disorders0/1970/1982/37
PneumoniaInfections and infestations6/1974/1980/37
Urinary tract infectionInfections and infestations2/1976/1981/37
Acute myocardial infarctionCardiac disorders2/1971/1981/37
Cardiac failureCardiac disorders1/1971/1981/37
Abdominal painGastrointestinal disorders0/1971/1981/37
SepsisInfections and infestations1/1973/1981/37
Most frequent other events
Showing 10 of 648
Most frequent other events
EventEnzalutamideDB Phase: BicalutamideOpen Label Phase: Bicalutamide Crossover to Enzalutamide
FatigueGeneral disorders82/19756/19810/37
DiarrhoeaGastrointestinal disorders26/19729/1989/37
NauseaGastrointestinal disorders38/19732/1989/37
ArthralgiaMusculoskeletal and connective tissue disorders45/19729/1985/37
FallInjury, poisoning and procedural complications39/19719/1988/37
Back painMusculoskeletal and connective tissue disorders41/19734/1983/37
Urinary tract infectionInfections and infestations14/19721/1987/37
Hot flushVascular disorders34/19720/1982/37
ConstipationGastrointestinal disorders29/19733/1986/37
DizzinessNervous system disorders26/19715/1986/37

Baseline characteristics

Age, Customized
Age, Customized(Participants)EnzalutamideBicalutamideTotal
< 65 years392564
65-74 years8276158
≥ 75 years7797174
Sex/Gender, Customized
Sex/Gender, Customized(Participants)EnzalutamideBicalutamideTotal
Male198198396
Region of Enrollment
Region of Enrollment(Participants)EnzalutamideBicalutamideTotal
United States198198396
08

Study locations

109 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham,IDS Pharmacy
    Birmingham, Alabama 35249, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Desert Springs Cancer Care
    Scottsdale, Arizona 85255, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85704, United States
  • Arizona Oncology Associates, PC - HOPE
    Tucson, Arizona 85710, United States
  • Urological Associates of Southern Arizona, PC
    Tucson, Arizona 85715, United States
  • Urological Associates of Southern Arizona, PC
    Tucson, Arizona 85741, United States
  • Southern California Permanente Medical Group
    Anaheim, California 92806, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Antioch, California 94509, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Antioch, California 94531, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Fairfield, California 94533-6901, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Gilroy, California 95020, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • UCLA Clark Urology Clinic
    Los Angeles, California 90095, United States
  • UCLA Department of Pharmaceutical Services
    Los Angeles, California 90095, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Martinez, California 94553, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Milpitas, California 95035-5491, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Modesto, California 95356, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Moutain View, California 94041, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Napa, California 94558-3313, United States
  • Kaiser Permanente Medical Center
    Oakland, California 94611, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Pleasanton, California 94558, United States
  • Kaiser Permanente Medical Center Lab Drawing Station
    Redwood City, California 94063, United States
  • Kaiser Permanente Medical Center
    Roseville, California 95661, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Kaiser Permanente Medical Center
    Sacramento, California 95825, United States
  • San Bernardino Urological Associates Medical Group
    San Bernardino, California 92404, United States
  • Southern California Permanente Medical Group
    San Diego, California 92120, United States
  • Kaiser Permanente Medical Center
    San Francisco, California 94115, United States
  • Kaiser Permanente Medical Center
    San Jose, California 95119, United States
  • Kaiser Permanente Medical Center
    San Leandro, California 94577, United States
  • Southern California Permanente Medical Group
    San Marcos, California 92078, United States
  • Kaiser Permanente Medical Center
    Santa Clara, California 95051, United States
  • Skyline Urology
    Sherman Oaks, California 91411, United States
  • Kaiser Permanente Medical Center
    South San Francisco, California 94080, United States
  • Standford Health Care
    Stanford, California 94305, United States
  • Skyline Urology
    Torrance, California 90505, United States
  • Kaiser Permanente Medical Center
    Vallejo, California 94589, United States
  • Kaiser Permanente Medical Center
    Walnut Creek, California 94596, United States
  • Anschutz Cancer Center Pavilion Pharmacy
    Aurora, Colorado 80045, United States
  • Anschutz Inpatient Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Cancer Center, Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • The Urology Center of Colorado
    Denver, Colorado 80211, United States
  • George Washington University - Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Advanced Urology institute
    Daytona Beach, Florida 32114, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32207, United States
  • East Coast Institute for Research, LLC
    Jacksonville, Florida 32216, United States
  • Specialists In Urology
    Naples, Florida 34102, United States
  • First Urology, PSC
    Jeffersonville, Indiana 47130, United States
  • Metairie Oncologist, LLC
    Metairie, Louisiana 70006, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Regional Urology, LLC
    Shreveport, Louisiana 71106, United States
  • Chesapeake Urology Research Associates
    Towson, Maryland 21204, United States
  • Michigan Institute of Urology
    Troy, Michigan 48084, United States
  • Minnesota Oncology Hematology, P.A.
    Edina, Minnesota 55435-2150, United States
  • Minnesota Oncology Hematology, P.A.
    Woodbury, Minnesota 55125, United States
  • Barnes-Jewish West County Hospital
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University Infusion Center Pharmacy
    Saint Louis, Missouri 63110, United States
  • Washington University, School of Medicine, 7th Floor, Center for Advanced Medicine
    Saint Louis, Missouri 63110, United States
  • Siteman Cancer Center - South County
    Saint Louis, Missouri 63129, United States
  • GU Research network,LLC / Urology Cancer Center
    Omaha, Nebraska 68130, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • AccuMed Research Associates
    Garden City, New York 11530, United States
  • Premier Medical Group of the Hudson Valley PC
    Poughkeepsie, New York 12601, United States
  • Associated Medical Professionals of NY, PLLC
    Syracuse, New York 13210, United States
  • Carolinas Medical Center-Steelcreek
    Charlotte, North Carolina 28278, United States
  • Carolina Clinical Trials, LLC
    Concord, North Carolina 28025, United States
  • Carolina Urology Partners, PLLC
    Concord, North Carolina 28025, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Investigational Chemotherapy Services
    Durham, North Carolina 27710, United States
  • Alliance Urology Specialists, PA
    Greensboro, North Carolina 27403, United States
  • Rowan Regional Medical Center
    Salisbury, North Carolina 28144, United States
  • Wake Forest Baptist Health Urology
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • TriState Urologic Services PSC Inc., dba The Urology Group
    Cincinnati, Ohio 45212, United States
  • Cleveland Clinic Taussig Cancer Institute
    Cleveland, Ohio 44195, United States
  • Peace Harbor Hospital
    Florence, Oregon 97439, United States
  • Salem Hospital
    Salem, Oregon 97301, United States
  • Oregon Urology Institute
    Springfield, Oregon 97477, United States
  • Sacred Heart Nuclear Medicine
    Springfield, Oregon 97477, United States
  • Lancaster Urology
    Lancaster, Pennsylvania 17604, United States
  • Jefferson Medical Oncology
    Philadelphia, Pennsylvania 19107, United States
  • Jefferson Urology Associates
    Philadelphia, Pennsylvania 19107, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Cancer Center Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Mount Nittany Physician Group
    State College, Pennsylvania 16801, United States
  • Mount Nittany Health
    State College, Pennsylvania 16803, United States
  • Charleston Hematology Oncology Associates, PA
    Charleston, South Carolina 29414, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology Associates P.C.
    Nashville, Tennessee 37209, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Urology Clinics of North Texas
    Dallas, Texas 75231, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology-Memorial City
    Houston, Texas 77024, United States
  • Urology San Antonio Research
    San Antonio, Texas 78229, United States

Showing the first 100 of 109 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):363-365. doi: 10.1038/s41391-021-00465-7. Epub 2021 Oct 7. Erratum In: Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597. doi: 10.1038/s41391-021-00477-3. PubMed 34621011 ↗
  • Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25. PubMed 26811535 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2012 to primary completion in Feb 2015, 30 months.

Results were first posted in May 2016, 1 year 3 months after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 30 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2012
First posted
Aug 14, 2012
StartActual
Aug 2012
Primary completionActual
Feb 2015
CompletionActual
Jan 2018
Results first posted
May 23, 2016
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01664923
Lead sponsor
Pfizer
Collaborators
Astellas Pharma Inc, Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Aug 14, 2012
Start date
Aug 2012
Primary completion
Feb 2015
Completion
Jan 2018
Results posted
May 23, 2016
Last update
Jan 30, 2019

Study contacts

Pfizer Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion